Imunon Inc. (CLSN)
NASDAQ: CLSN
· Real-Time Price · USD
1.95
-0.01 (-0.51%)
At close: Sep 21, 2022, 6:00 AM
Company Description
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies.
Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications.
The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies.
Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
Imunon Inc.
| Country | United States |
| IPO Date | Oct 27, 1993 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Michael Tardugno |
Contact Details
Address: 997 Lenox Dr Ste 100 Lawrence Township, New Jersey United States | |
| Website | https://celsion.com |
Stock Details
| Ticker Symbol | CLSN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000749647 |
| CUSIP Number | 15117N602 |
| ISIN Number | US15117N6022 |
| Employer ID | 52-1256615 |
| SIC Code | 2834 |
Key Executives
No executives data available.Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 09, 2025 | 4 | Filing |
| Aug 28, 2025 | 8-K | Current Report |
| Aug 13, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 06, 2025 | 4 | Filing |
| Aug 06, 2025 | 4 | Filing |
| Aug 06, 2025 | 4 | Filing |
| Aug 06, 2025 | 4 | Filing |
| Aug 06, 2025 | 4 | Filing |
| Aug 06, 2025 | 4 | Filing |